FDA to revise Novartis' Gilenya label to reflect brain infection risk
August 04, 2015 at 14:28 PM EDT
Aug 4 (Reuters) - The U.S. Food and Drug Administration said it will update the label of Novartis AG's multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use.
